Is hCG FDA-approved for men?

Yes, and it is the only agent in its class that is. PREGNYL (BLA 017692, Organon LLC) and NOVAREL (BLA 017016, Ferring Pharmaceuticals, initial US approval 1974) both list among their indications "Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males.", alongside prepubertal cryptorchidism and ovulation induction in women. The AUA guideline makes the same point about the agents commonly used for fertility preservation in men: "Clinicians should understand that of these agents, only hCG has been approved by the FDA for use in males." Be precise about what that approval covers, though. Hypogonadotropic hypogonadism means a pituitary problem. It is not an approval for primary testicular failure, and it is not an approval for maintaining testicular size or sperm counts while on testosterone — neither hCG label mentions either of those.

Does hCG protect fertility on TRT?

Nothing on either hCG label says so — the word "spermatogenesis" appears zero times in both, and neither document mentions concomitant testosterone at all. The support is literature. Hsieh 2013 (PMID 23260550) followed 26 hypogonadal men on testosterone plus 500 IU hCG intramuscularly every other day and reported that "No patient became azoospermic during concomitant testosterone replacement and human chorionic gonadotropin therapy", concluding that "Low dose human chorionic gonadotropin appears to maintain semen parameters in hypogonadal men on testosterone replacement therapy". Coviello 2005 (PMID 15713727) supplies the mechanism: testosterone alone suppressed intratesticular testosterone by 94%, and low-dose hCG held it in the normal range. Weigh the evidence honestly: 26 men, retrospective, mean follow-up 6.2 months, no control arm — and Coviello's own paper says the intratesticular concentration actually required to maintain spermatogenesis was still to be determined. It is a reasonable, mechanistically coherent practice with modest evidence behind it, and it is off-label.

Can hCG replace testosterone instead of being added to it?

For one kind of hypogonadism, on-label, yes — and for the other, no. Both hCG labels are indicated for "selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males", which is the same condition listed second on the Depo-Testosterone label. So in secondary hypogonadism both drugs are licensed options. Primary hypogonadism is different: the testosterone label covers "testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy" and neither hCG label covers anything comparable. That is mechanism rather than paperwork. Both hCG labels read: "It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone." It needs a testis that can still respond. What the labels do not settle is which works better in the men where both are options: no trial on either label compares them, and this page states no difference.

How long does reconstituted hCG last in the fridge?

It depends which product you have, and the two approved labels genuinely disagree. PREGNYL states, in capitals: "IF NEEDED, THE RECONSTITUTED SOLUTION IS STABLE FOR 60 DAYS WHEN REFRIGERATED. DO NOT FREEZE. USE THE RECONSTITUTED SOLUTION WITHIN 60 DAYS OF RECONSTITUTION." NOVAREL states: "REFRIGERATE RECONSTITUTED PRODUCT AT 2° to 8°C (36° to 46°F) AND USE WITHIN 30 DAYS." 60 days and 30 days are both correct — for their own product, with their own diluent. PREGNYL ships a phosphate-buffered, benzyl-alcohol-preserved solvent in a two-vial pack; NOVAREL is reconstituted with Bacteriostatic Water for Injection containing 0.9% benzyl alcohol. This page does not average them, does not print a range and does not pick a side. Read the carton in front of you.

Should hCG be injected into muscle or under the skin?

Both approved labels say muscle, and only muscle. PREGNYL: "For intramuscular use only. Each multiple-dose vial is to be used for one patient." NOVAREL heads its dosage and administration section "(Intramuscular Use Only)". Subcutaneous hCG drawn into an insulin syringe is extremely common in men's health practice and is not the labelled route for either product — the Hsieh series that most people cite for fertility preservation used intramuscular dosing. This is a change of route, which is a clinical decision rather than a preference: ask your prescriber to specify it rather than switching on your own. One practical consequence is that a fixed 1/2-inch insulin needle cannot reach muscle in most adults, so choosing the barrel quietly chooses the route.

What dose of hCG does the label actually state?

For the male indication, both labels give the same two alternatives, and both introduce them with the same hedge: "The following regimens have been advocated by various authorities." The first is 500 to 1,000 USP units three times a week for three weeks, followed by the same dose twice a week for three weeks. The second is 4,000 USP units three times weekly for six to nine months, following which the dosage may be reduced to 2,000 USP units three times weekly for an additional three months. Two things are worth noticing. Those are regimens for treating hypogonadotropic hypogonadism, not for running hCG alongside testosterone — no label states a dose for that use, because it is not a labelled use. And "units" is doing double duty: USP units measure hormone, while the marks on a U-100 insulin barrel measure volume. At 1,000 IU/mL a 500 IU dose is 0.5 mL, which is 50 marks, not 500. Always work from the concentration on your own vial.

Does TRT definitely suppress sperm production?

The testosterone labels are explicit about the mechanism and the effect, and they are the strongest reason to raise fertility before starting rather than afterwards. Depo-Testosterone states that "endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH)" and that "At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH)", with "Oligospermia may occur after prolonged administration or excessive dosage" in its precautions. The AndroGel Highlights put it as Warnings and Precautions 5.8: "Potential for Adverse Effects on Spermatogenesis: Exogenous administration of androgens may lead to azoospermia." Hsieh 2013 gives the background figure from the clinical literature — testosterone replacement "impairs spermatogenesis, leading to azoospermia in 40% of patients" — which is a statement in that paper's introduction rather than one of its own findings, and is presented here as such.

Head to head

TRT vs hCG

hCG is the one agent in this class with a genuine FDA-approved use in men, and its labelled indication overlaps testosterone's. What separates them is which kind of hypogonadism you have — and one thing neither hCG label mentions at all.

Reviewed September 2026

The short answer

Unlike almost everything else men are offered alongside or instead of testosterone, hCG is genuinely approved, and genuinely approved in men. PREGNYL (BLA 017692, Organon) and NOVAREL (BLA 017016, Ferring) both list, among their indications, "Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males." The AUA guideline makes the same point about the class it belongs to: "Clinicians should understand that of these agents, only hCG has been approved by the FDA for use in males." That puts this comparison on a completely different footing from testosterone against a compounded SERM.

And the two indications overlap. The Depo-Testosterone label's second listed indication is "Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation." — the same condition, described in almost the same words. Two approved drugs, opposite mechanisms, one shared licence.

What separates them on the label is the OTHER indication, and it is the line that should decide the question. Testosterone is also approved for "Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy." hCG is not approved for that and could not be: it works by stimulating the Leydig cells of the testis, so it needs a testis that can still respond. If the problem is the pituitary signal, both drugs are on-label. If the testis itself has failed, only one of them has anything to act on.

Now the part every article gets wrong. The reason most men in this vertical are offered hCG is fertility, and the word "spermatogenesis" does not appear in the PREGNYL label or the NOVAREL label. Not once, in either. Neither label makes any claim about sperm counts, fertility preservation, or being taken alongside testosterone. Both testosterone labels, by contrast, state the suppression plainly. So the fertility case for hCG is a literature case, not a label case — and the literature is real, small, and worth reading rather than being summarised as a slogan.

5 of 19 dimensions are materially the same. They are marked below rather than dressed up as differences.

Testosterone replacement therapy

Depo-Testosterone · testosterone cypionate

Exogenous testosterone, given into muscle. Approved for both primary and hypogonadotropic hypogonadism, and it works whether or not your own axis can respond.

Dosing protocol →

hCG

Pregnyl · Novarel · chorionic gonadotropin

A gonadotropin that stimulates your own Leydig cells. The only agent in this class with an FDA-approved male indication — and it needs testes that can still respond.

Dosing protocol →

Side by side

Every row carries how well supported it is. A claim that only reflects common practice is labelled as such rather than presented as fact.

Dimension	Testosterone replacement therapy	hCG	Basis
FDA approvalsame	Approved	Approved — BLA 017692 and BLA 017016	labelThe row that separates hCG from every other ancillary in this space. Anastrozole is approved but only in women with breast cancer; clomiphene is approved but only for ovulation induction; enclomiphene has never been approved for anything. hCG has two live biologics licence applications, PREGNYL (Organon) and NOVAREL (Ferring, initial US approval 1974), and both of them name a male use.
Approved for use in mensame	Yes	Yes	labelBoth hCG labels, verbatim: "Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males." That is a real on-label male indication, not an off-label convention. The AUA guideline says the same thing about the whole class: "Clinicians should understand that of these agents, only hCG has been approved by the FDA for use in males."
Hypogonadotropic hypogonadismsame	Indicated	Indicated	labelThe overlap, and it is almost word for word. Depo-Testosterone: "Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation." hCG: "Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males." Secondary hypogonadism — the pituitary signal, not the testis — is the one condition both of these approved drugs are licensed to treat.
Primary hypogonadism — testicular failure	Indicated	Not indicated, and mechanistically cannot be	labelThe line that should decide the question, and almost nothing written about hCG draws it. Depo-Testosterone's first indication is "Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy." Neither hCG label carries anything comparable. Both describe the mechanism that explains why, in the same sentence: "It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone." A drug that works by asking the testis to produce testosterone has nothing to ask when the testis is the problem.
Direction of effect on LH and FSH	Suppressed — it is in the label's own mechanism section	Bypassed — hCG substitutes for LH at the receptor	labelDepo-Testosterone, verbatim: "endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH)" and "At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH)." hCG does not raise your LH; it acts in its place, and both labels note that it "appears to have a small degree of FSH activity as well". This is why the two can be given together, which is what most men in this vertical are actually doing.
What the label says about sperm production	Suppression is stated outright	Nothing. The word does not appear	labelThe single most important row on this page and the one no competitor prints. "Spermatogenesis" appears zero times in the PREGNYL label and zero times in the NOVAREL label; both were searched in full on 2026-09-20. Neither makes any claim about sperm counts, fertility or concomitant testosterone. The testosterone labels are explicit in the other direction: Depo-Testosterone states that "Oligospermia may occur after prolonged administration or excessive dosage", and the AndroGel Highlights carry "Potential for Adverse Effects on Spermatogenesis: Exogenous administration of androgens may lead to azoospermia (5.8)".
What the literature says about sperm production	Azoospermia in a substantial minority	No patient became azoospermic in a 26-man series	literatureHsieh 2013 (PMID 23260550), 26 hypogonadal men on testosterone plus 500 IU hCG intramuscularly every other day: "No patient became azoospermic during concomitant testosterone replacement and human chorionic gonadotropin therapy", and "Low dose human chorionic gonadotropin appears to maintain semen parameters in hypogonadal men on testosterone replacement therapy." Read the size before the conclusion: 26 men, retrospective chart review, mean follow-up 6.2 months, no control arm. The paper's own background sentence supplies the figure in the left-hand cell — testosterone replacement "impairs spermatogenesis, leading to azoospermia in 40% of patients".
What happens inside the testis	Intratesticular testosterone falls by about 94%	Low-dose hCG holds it in the normal range	literatureCoviello 2005 (PMID 15713727), the pharmacology behind the practice: 29 men with normal reproductive physiology given 200 mg testosterone enanthate weekly plus saline or 125, 250 or 500 IU hCG every other day for 3 weeks. "ITT was suppressed by 94% (1234 to 72 nmol/liter) in the T enanthate/placebo group", and "relatively low dose hCG maintains ITT within the normal range in healthy men with gonadotropin suppression." The paper refuses the next step and so does this page: "Extensions of this study will allow determination of the ITT concentration threshold required to maintain spermatogenesis in man." No threshold has been stated here because none was established there.
Labelled dose	50 – 400 mg every two to four weeks	500 to 1,000 USP units three times a week for three weeks, followed by the same dose twice a week for three weeks	labelDepo-Testosterone, verbatim: "For replacement in the hypogonadal male, 50 - 400 mg should be administered every two to four weeks." Both hCG labels give two alternatives for the male indication — the one shown, or "4,000 USP units three times weekly for six to nine months, following which the dosage may be reduced to 2,000 USP units three times weekly for an additional three months" — and both introduce them with the caveat "The following regimens have been advocated by various authorities". Note what is missing: no hCG label states a dose for use alongside testosterone, because that is not a labelled use.
What the dose is measured in	Milligrams of ester in oil	USP units of hormone in a reconstituted solution	labelThere is no conversion between these and none is attempted here. They are different quantities. A further trap sits inside the hCG column: USP units are units of hormone, while the marks on an insulin barrel are units of volume, 100 to the millilitre. At 1,000 IU/mL a 500 IU dose is 0.5 mL, which is 50 marks on a U-100 barrel and not 500 of them — and the concentration depends entirely on how much diluent went into your vial.
Labelled routesame	Intramuscular only	Intramuscular only	labelDepo-Testosterone: "DEPO-Testosterone Injection is for intramuscular use only. It should not be given intravenously." PREGNYL: "For intramuscular use only. Each multiple-dose vial is to be used for one patient." NOVAREL heads its dosage section "(Intramuscular Use Only)". Both drugs are labelled the same way here, which surprises people who have only ever seen hCG drawn into an insulin syringe.
How it is actually injected	Intramuscular, as labelled	Very commonly subcutaneous, which no label permits	practiceSubcutaneous hCG on a fixed-needle insulin syringe is close to universal in men's health practice, and it is not the labelled route for either product. It is also not a change to make on your own: a fixed 1/2-inch insulin needle cannot deliver an intramuscular injection in most adults even if you intended one, so switching barrels silently switches route. Ask the prescriber to write the route down.
Preparation before the first dose	None — the vial is ready to draw	Reconstitution, and the diluent volume sets everything	labelA ready-to-use oil against a lyophilised cake. NOVAREL tabulates the two reconstitutions it supports: 1 mL of bacteriostatic water gives 10,000 IU/mL from the 10,000 IU vial and is for "Administer entire dose at once"; 10 mL gives 1,000 IU/mL and is for "Multiple dose administration, refrigerate between doses". PREGNYL instructs you to "Remove 1 to 10 mL of solvent and add to vial with lyophilized powder; agitate gently until powder is completely dissolved in solution. Do not shake." The same vial can be ten different concentrations.
How long it lasts once opened or mixed	Per your pharmacy's beyond-use date for a multi-dose vial	60 days for PREGNYL, 30 days for NOVAREL — not an average	labelThe two approved hCG products genuinely disagree and both are right about themselves. PREGNYL: "IF NEEDED, THE RECONSTITUTED SOLUTION IS STABLE FOR 60 DAYS WHEN REFRIGERATED. DO NOT FREEZE. USE THE RECONSTITUTED SOLUTION WITHIN 60 DAYS OF RECONSTITUTION." NOVAREL: "REFRIGERATE RECONSTITUTED PRODUCT AT 2° to 8°C (36° to 46°F) AND USE WITHIN 30 DAYS." PREGNYL ships its own phosphate-buffered solvent; NOVAREL is reconstituted with Bacteriostatic Water for Injection. Read the carton you have rather than the number you remember.
Controlled substance status	Schedule III	No DEA schedule on the label	labelThe Depo-Testosterone label carries CIII on its title line. Neither hCG label carries a schedule. This affects how each is prescribed, refilled and transported, and it is a regulatory fact rather than a safety judgement — being unscheduled says nothing about how carefully a drug should be used.
Labelled monitoring	Haemoglobin and haematocrit, periodically	None for the male indication	labelDepo-Testosterone, verbatim: "Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration." Neither hCG label sets a monitoring schedule for the male indication. The nearest thing to guidance is a timing point from the AUA rather than a protocol: "Patients using anastrozole, clomiphene citrate, or hCG should be tested no earlier than four weeks." Testing sooner measures a system that has not settled.
Weight loss	Not an indication	The label refuses it in capital letters	labelBoth hCG labels open their indications section with this, in upper case, before naming a single approved use: "HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION..." It is unusual for a label to shout, and the reason is that hCG diet products have been sold against that sentence for decades.
Which raises testosterone moresame	Not established against the other	Not established against the other	labelPrinted rather than omitted. No trial on either label compares testosterone replacement with hCG monotherapy, and this page cites none. Nor is there a labelled dose, ratio or schedule for giving hCG alongside testosterone — the combination that most men in this vertical are actually on is entirely off-label, however routine it has become.
What the guidelines say	Recommended, with monitoring, in confirmed hypogonadism	Permitted for fertility, with the approval caveat attached	guidelineAUA statement 27, verbatim: "Clinicians may use aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination thereof in men with testosterone deficiency desiring to maintain fertility. (Conditional Recommendation; Evidence Level: Grade C)" — and then the sentence that separates hCG from the rest of that list: "Clinicians should understand that of these agents, only hCG has been approved by the FDA for use in males." Note the strength: Conditional Recommendation, Evidence Level Grade C. The guideline permits hCG for fertility; it does not claim the evidence is strong.

label: Stated on the FDA label
guideline: Clinical practice guideline
literature: Published literature
practice: Common practice, not documented

Which one

Choose Testosterone replacement therapy if

Your hypogonadism is primary — testicular failure rather than a pituitary problem. hCG is not indicated for that and mechanistically has nothing to act on; testosterone works regardless.
You want the drug with the labelled monitoring, the labelled dose range and the every-two-to-four-week cadence rather than an injection every other day.
Fertility is not a current concern, or you are prepared to add hCG alongside — which is what the literature on this page actually studied, rather than either drug alone.
You want your levels to be predictable. An oil depot with a stated dose range behaves more consistently than a reconstituted powder whose concentration depends on how much water went into the vial.

Choose hCG if

Your hypogonadism is secondary — the pituitary signal, not the testis. Both drugs are on-label for that, and only one of them leaves your own axis running.
Preserving your own sperm production is the reason you are asking. The evidence is literature rather than label, and it is small, but hCG is the only agent in this class with any FDA-approved male use at all.
You would rather stimulate your own production than replace it, and you accept an injection every other day in the trials that studied it rather than one every two to four weeks.
You are already on testosterone and want to add hCG rather than swap. That is what Hsieh 2013 and Coviello 2005 both examined — combination, not substitution.

Three things to hold on to. First, the fertility argument for hCG is not on its label: the word "spermatogenesis" appears nowhere in either approved hCG document, and every claim on this page about sperm counts is cited to a paper, with its size attached. Second, the combination almost everyone in this vertical is actually on — testosterone plus hCG — has no labelled dose, ratio or schedule anywhere, and neither label acknowledges the other drug. That does not make it wrong; it makes it something a prescriber should be writing down and monitoring, not something to copy from a forum. Third, and most practically: hCG is a two-product drug that disagrees with itself. PREGNYL's reconstituted solution lasts 60 days refrigerated and NOVAREL's lasts 30; both are intramuscular only; and the same vial can be ten different concentrations depending on the diluent volume. Whatever you decide, the numbers that matter are the ones on the carton in front of you.

Frequently asked questions

Is hCG FDA-approved for men?: Yes, and it is the only agent in its class that is. PREGNYL (BLA 017692, Organon LLC) and NOVAREL (BLA 017016, Ferring Pharmaceuticals, initial US approval 1974) both list among their indications "Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males.", alongside prepubertal cryptorchidism and ovulation induction in women. The AUA guideline makes the same point about the agents commonly used for fertility preservation in men: "Clinicians should understand that of these agents, only hCG has been approved by the FDA for use in males." Be precise about what that approval covers, though. Hypogonadotropic hypogonadism means a pituitary problem. It is not an approval for primary testicular failure, and it is not an approval for maintaining testicular size or sperm counts while on testosterone — neither hCG label mentions either of those.
Does hCG protect fertility on TRT?: Nothing on either hCG label says so — the word "spermatogenesis" appears zero times in both, and neither document mentions concomitant testosterone at all. The support is literature. Hsieh 2013 (PMID 23260550) followed 26 hypogonadal men on testosterone plus 500 IU hCG intramuscularly every other day and reported that "No patient became azoospermic during concomitant testosterone replacement and human chorionic gonadotropin therapy", concluding that "Low dose human chorionic gonadotropin appears to maintain semen parameters in hypogonadal men on testosterone replacement therapy". Coviello 2005 (PMID 15713727) supplies the mechanism: testosterone alone suppressed intratesticular testosterone by 94%, and low-dose hCG held it in the normal range. Weigh the evidence honestly: 26 men, retrospective, mean follow-up 6.2 months, no control arm — and Coviello's own paper says the intratesticular concentration actually required to maintain spermatogenesis was still to be determined. It is a reasonable, mechanistically coherent practice with modest evidence behind it, and it is off-label.
Can hCG replace testosterone instead of being added to it?: For one kind of hypogonadism, on-label, yes — and for the other, no. Both hCG labels are indicated for "selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males", which is the same condition listed second on the Depo-Testosterone label. So in secondary hypogonadism both drugs are licensed options. Primary hypogonadism is different: the testosterone label covers "testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy" and neither hCG label covers anything comparable. That is mechanism rather than paperwork. Both hCG labels read: "It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone." It needs a testis that can still respond. What the labels do not settle is which works better in the men where both are options: no trial on either label compares them, and this page states no difference.
How long does reconstituted hCG last in the fridge?: It depends which product you have, and the two approved labels genuinely disagree. PREGNYL states, in capitals: "IF NEEDED, THE RECONSTITUTED SOLUTION IS STABLE FOR 60 DAYS WHEN REFRIGERATED. DO NOT FREEZE. USE THE RECONSTITUTED SOLUTION WITHIN 60 DAYS OF RECONSTITUTION." NOVAREL states: "REFRIGERATE RECONSTITUTED PRODUCT AT 2° to 8°C (36° to 46°F) AND USE WITHIN 30 DAYS." 60 days and 30 days are both correct — for their own product, with their own diluent. PREGNYL ships a phosphate-buffered, benzyl-alcohol-preserved solvent in a two-vial pack; NOVAREL is reconstituted with Bacteriostatic Water for Injection containing 0.9% benzyl alcohol. This page does not average them, does not print a range and does not pick a side. Read the carton in front of you.
Should hCG be injected into muscle or under the skin?: Both approved labels say muscle, and only muscle. PREGNYL: "For intramuscular use only. Each multiple-dose vial is to be used for one patient." NOVAREL heads its dosage and administration section "(Intramuscular Use Only)". Subcutaneous hCG drawn into an insulin syringe is extremely common in men's health practice and is not the labelled route for either product — the Hsieh series that most people cite for fertility preservation used intramuscular dosing. This is a change of route, which is a clinical decision rather than a preference: ask your prescriber to specify it rather than switching on your own. One practical consequence is that a fixed 1/2-inch insulin needle cannot reach muscle in most adults, so choosing the barrel quietly chooses the route.
What dose of hCG does the label actually state?: For the male indication, both labels give the same two alternatives, and both introduce them with the same hedge: "The following regimens have been advocated by various authorities." The first is 500 to 1,000 USP units three times a week for three weeks, followed by the same dose twice a week for three weeks. The second is 4,000 USP units three times weekly for six to nine months, following which the dosage may be reduced to 2,000 USP units three times weekly for an additional three months. Two things are worth noticing. Those are regimens for treating hypogonadotropic hypogonadism, not for running hCG alongside testosterone — no label states a dose for that use, because it is not a labelled use. And "units" is doing double duty: USP units measure hormone, while the marks on a U-100 insulin barrel measure volume. At 1,000 IU/mL a 500 IU dose is 0.5 mL, which is 50 marks, not 500. Always work from the concentration on your own vial.
Does TRT definitely suppress sperm production?: The testosterone labels are explicit about the mechanism and the effect, and they are the strongest reason to raise fertility before starting rather than afterwards. Depo-Testosterone states that "endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH)" and that "At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH)", with "Oligospermia may occur after prolonged administration or excessive dosage" in its precautions. The AndroGel Highlights put it as Warnings and Precautions 5.8: "Potential for Adverse Effects on Spermatogenesis: Exogenous administration of androgens may lead to azoospermia." Hsieh 2013 gives the background figure from the clinical literature — testosterone replacement "impairs spermatogenesis, leading to azoospermia in 40% of patients" — which is a statement in that paper's introduction rather than one of its own findings, and is presented here as such.

Sources

Next steps

Compare online TRT providersWhich platforms prescribe hCG alongside testosterone, which will not, and what monitoring is included.TRT — how it works and what it costsWhat gets tested before a prescription, and where fertility fits into the conversation.

Other comparisons

Educational reference, not medical advice. Which medication suits you is a decision for your prescriber.